King, Acura get FDA response letter

The FDA has issued a Complete Response Letter to King Pharmaceuticals and Acura Pharmaceuticals regarding their NDA for the pain drug Acurox. The agency has questions about the potential abuse deterrent benefits of Acurox, which the two companies say they can address without having to conduct additional clinical trials. Report

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.